Recurrent Soft Tissue Sarcoma: Clinical Trials

4 trials for Recurrent Soft Tissue Sarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 4
Phase 11Completed 1

Follow Recurrent Soft Tissue Sarcoma: new trials by email Literature Review of Recurrent Soft Tissue Sarcoma trials Research Report on Recurrent Soft Tissue Sarcoma

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Phase 2CompletedNational Cancer Institute (NCI)232018-08-132026-04-03
Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma
Pembrolizumab, Radiation Therapy - Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
Phase 1 / Phase 2CompletedFred Hutchinson Cancer Center272018-03-282024-07-23
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)182017-11-282026-04-21
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)202017-11-132026-04-13

Narrower conditions

Sarcoma (4)  ·  Ependymoma (3)  ·  Glioma (3)  ·  Hepatoblastoma (3)  ·  Histiocytosis, Langerhans-Cell (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Medulloblastoma (3)  ·  Neuroblastoma (3)  ·  Neuroectodermal Tumors, Primitive, Peripheral (3)  ·  Osteosarcoma (3)  ·  Rhabdoid Tumor (3)  ·  Rhabdomyosarcoma (3)  ·  Sarcoma, Ewing (3)  ·  Wilms Tumor (3)  ·  Central Nervous System Neoplasms (2)

Broader conditions

Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms, Connective and Soft Tissue (4)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Female Urogenital Diseases (3)  ·  Female Urogenital Diseases and Pregnancy Complications (3)  ·  Genetic Diseases, Inborn (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Histiocytosis (3)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Kidney Diseases (3)  ·  Kidney Neoplasms (3)  ·  Lung Diseases (3)  ·  Lung Diseases, Interstitial (3)

Interventions

LY3023414 (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Phantoms, Imaging (1)  ·  Radiation (1)  ·  Radiotherapy (1)  ·  Specimen Handling (1)  ·  X-Rays (1)  ·  palbociclib (1)  ·  pembrolizumab (1)  ·  tazemetostat (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Fred Hutchinson Cancer Center (1)

Countries

United States (4)  ·  Puerto Rico (3)

Top investigators

Lee Cranmer (1)  ·  Rajen Mody (1)  ·  Susan N Chi (1)  ·  Theodore W Laetsch (1)

Results publications

PMID 31401903, PMID 39298716

NIH funding

U10CA180886 (3)